Want to see AU:CYC full AI Analyst Report?
Top Page
Cyclopharm Limited
(Sydney:CYC)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.34
▼(-33.85% Downside)
Action:Reiterated
Date:10/16/26
The score is primarily held down by weak financial performance—worsening profitability, high ongoing cash burn, and rising leverage. Technicals reinforce the risk, with the stock below major moving averages and bearish momentum. Valuation provides limited offset because a negative P/E reflects lack of profitability and no dividend yield is available.
Positive Factors
Revenue Growth
Steady revenue growth through 2025 indicates improving commercial traction and ongoing demand for the company’s offerings. If maintained, this expanding revenue base can support operating leverage, broader market penetration, and eventual recovery in profitability.
Negative Factors
Severe Profitability Deterioration
Negative gross profit means costs exceeded revenue at the gross-profit level, making the current business economics unsustainable without material improvement. Widening losses reduce internal funding capacity and increase the importance of a lasting margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Steady revenue growth through 2025 indicates improving commercial traction and ongoing demand for the company’s offerings. If maintained, this expanding revenue base can support operating leverage, broader market penetration, and eventual recovery in profitability.
Read all positive factors
Cyclopharm Limited (CYC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$46.52M
Dividend Yield0.64%
Average Volume (3M)83.53K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth12.05%
EPS Growth-31.71%
CountryAU
Employees104
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.16
Shares Outstanding125,734,146
10 Day Avg. Volume96,612
30 Day Avg. Volume83,529
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside92.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)AU$36.60M
Cyclopharm Limited Business Overview & Revenue Model
Company Description
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business ...
Cyclopharm Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.42M | 32.33M | 27.57M | 26.34M | 23.22M | 17.70M |
| Gross Profit | -486.17K | -1.46M | 17.93M | 16.08M | 5.94M | 3.20M |
| EBITDA | -16.10M | -16.41M | -13.05M | -3.84M | -6.47M | -5.79M |
| Net Income | -18.32M | -17.22M | -13.20M | -4.70M | -6.61M | -5.04M |
Balance Sheet | ||||||
| Total Assets | 49.68M | 46.10M | 62.13M | 45.91M | 49.54M | 55.74M |
| Cash, Cash Equivalents and Short-Term Investments | 12.25M | 6.63M | 20.57M | 11.73M | 20.30M | 29.25M |
| Total Debt | 7.80M | 14.92M | 8.29M | 4.23M | 4.33M | 4.51M |
| Total Liabilities | 17.81M | 18.99M | 19.40M | 13.65M | 13.01M | 12.67M |
| Stockholders Equity | 31.86M | 27.11M | 42.73M | 32.26M | 36.54M | 43.07M |
Cash Flow | ||||||
| Free Cash Flow | -19.49M | -19.32M | -13.55M | -7.74M | -8.21M | -2.79M |
| Operating Cash Flow | -17.51M | -17.33M | -12.57M | -7.20M | -6.66M | -1.63M |
| Investing Cash Flow | 3.08M | 3.00M | -971.86K | -508.47K | -1.55M | -1.16M |
| Financing Cash Flow | 12.64M | -1.12M | 22.22M | -1.02M | -725.64K | 30.17M |
Cyclopharm Limited Technical Analysis
Negative
0.52
Price Trends
0.47
Negative
0.50
Negative
0.66
Negative
Market Momentum
-0.03
Positive
33.72
Neutral
37.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYC, the sentiment is Negative. The current price of 0.52 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.47, and below the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 33.72 is Neutral, neither overbought nor oversold. The STOCH value of 37.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CYC.
Cyclopharm Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$45.95M | 209.09 | 0.93% | ― | 18.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$143.62M | -16.98 | -46.84% | ― | ― | 20.40% | |
44 Neutral | AU$27.53M | -1.50 | -245.90% | ― | 43.92% | 65.23% | |
43 Neutral | AU$32.37M | -3.22 | -188.06% | ― | 15.58% | 37.17% | |
41 Neutral | AU$46.52M | -2.34 | -62.14% | 0.64% | 12.05% | -31.71% | |
40 Underperform | AU$466.14M | -8.23 | -184.93% | ― | -68.64% | 36.40% |
* Healthcare Sector Average
AU:CYC
Cyclopharm Limited
0.37
-0.30
-44.78%
AU:CMP
Compumedics Limited
0.23
-0.09
-28.13%
AU:MX1
Micro-X Ltd.
0.04
-0.07
-60.91%
AU:EMV
EMvision Medical Devices Ltd.
1.55
-0.31
-16.49%
AU:OSL
OncoSil Medical Ltd
0.75
-0.74
-49.70%
AU:IMR
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
1.30
-0.13
-9.09%
Cyclopharm Limited Corporate Events
Cyclopharm’s Technegas Secures China Endorsement, Strengthening Global Standard of Care
Oct 6, 2026
Cyclopharm’s flagship ventilation imaging agent Technegas has been named the preferred radiopharmaceutical for lung ventilation imaging in pulmonary embolism by seven leading Chinese medical societies. The expert consensus, published in a ke...
Cyclopharm Flags Uncertainties Around First-Half 2026 Results
Aug 23, 2026
Cyclopharm Limited has released its first half 2026 results presentation, framed with extensive cautionary language around the reliability of the information and projections it contains. The company stresses that its financial estimates and market...
Cyclopharm Delivers Higher Revenue but Wider Half-Year Loss
Aug 23, 2026
Cyclopharm Limited reported a 14% increase in revenue from ordinary activities to $17.52 million for the half year ended 30 June 2026, underscoring continued growth in demand for its nuclear medicine imaging solutions. Despite this top-line improv...
Technegas Secures Preferred Status in Landmark U.S. Lung Imaging Guidelines
Jul 28, 2026
Cyclopharm’s Technegas lung ventilation agent has been named the preferred ventilation agent in newly published international guidelines for ventilation‑perfusion pulmonary scintigraphy, marking the first update to U.S. lung imaging st...
Cyclopharm Flags Uncertainties Around Financial Projections in ausbiz Briefing
Jul 27, 2026
Cyclopharm Limited has released an ausbiz presentation outlining management’s views on the company’s anticipated future financial performance and the markets for its products. The document emphasises that the financial projections and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.